Verastem Up On Positive Data From Early-Stage Copiktra Study
Zacks Investment Research | Jun 24, 2019 08:33AM ET
Verastem, Inc. (NASDAQ:VSTM) presented encouraging data from phase I study that evaluated its leukemia drug, Copiktra (duvelisib), in patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL") at the International Conference on Malignant Lymphoma ("ICML").
The phase I study evaluated twice-daily 25mg or 75mg doses of Copiktra monotherapy or lead-in monotherapy to a combination regimen with romidepsin or Takeda's (NYSE:TAK) Velcade (bortezomib) in PTCL patients. Data from the phase I study demonstrated that Copiktra achieved compelling clinical activity.
The 75mg dose of drug achieved an objective response rate ("ORR") of 54% as monotherapy and 44% as lead-in monotherapy before romidepsin. The complete response rate ranged between 15% and 22%. The drug's 25mg dose as lead-in monotherapy before bortezomib achieved an ORR of 57%. The drug achieved a median progress-free-survival of 8.3 months and median overall survival was 16.2 months.
Following the announcement, shares of the company gained 13.8% on Jun 21. So far this year, Verastem has declined 46.1% against the agreement with China’s CSPC Pharmaceutical Group to develop and commercialize Copiktra for treating different types of cancer indications in China.
Furthermore, Verastem is developing an oral small molecule kinase inhibitor, defactinib, as treatment for ovarian cancer, pancreatic cancer, mesothelioma, non-small cell lung cancer, and other solid tumors. A phase Ib study is evaluating the candidate in combination with Merck's (NYSE:MRK) PD-1 inhibitor Keytruda as well as Eli Lilly’s Gemzar for treating patients with advanced pancreatic cancer.
Verastem, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.